Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023 Jan 18;15(3):595.
doi: 10.3390/cancers15030595.

Helicobacter Species and Hepato-Biliary Tract Malignancies: A Systematic Review and Meta-Analysis

Affiliations
Review

Helicobacter Species and Hepato-Biliary Tract Malignancies: A Systematic Review and Meta-Analysis

Beatriz Gros et al. Cancers (Basel). .

Abstract

Helicobacter species may cause chronic inflammation of the biliary tract, but its relationship with cancer is controversial. We performed a systematic review and meta-analysis to evaluate the association between Helicobacter species and hepatobiliary tract malignancies. Twenty-six studies (4083 patients) were included in qualitative synthesis, and 18 studies (n = 1895 qualified for meta-analysis. All studies were at high-intermediate risk of bias. Most studies combined several direct microbiological methods, mostly PCR (23 studies), culture (8 studies), and/or CLOtest (5 studies). Different specimens alone or in combination were investigated, most frequently bile (16 studies), serum (7 studies), liver/biliary tissue (8 studies), and gastric tissue (3 studies). Patients with Helicobacter species infection had an increased risk of hepatobiliary tract malignancies (OR = 3.61 [95% CI 2.18-6.00]; p < 0.0001), with high heterogeneity in the analysis (I2 = 61%; p = 0.0003). This effect was consistent when Helicobacter was assessed in bile (OR = 3.57 [95% CI 1.73-7.39]; p = 0.0006), gastric tissue (OR = 42.63 [95% CI 5.25-346.24]; p = 0.0004), liver/biliary tissue (OR = 4.92 [95% CI 1.90-12.76]; p = 0.001) and serum (OR = 1.38 [95% CI 1.00-1.90]; p = 0.05). Heterogeneity was reduced in these sub-analyses (I2 = 0-27%; p = ns), except for liver/biliary tissue (I2 = 57%; p = 0.02). In conclusion, based on low-certainty data, Helicobacter species chronic infection is associated with a tripled risk of hepatobiliary tract malignancy. Prospective studies are required to delineate public health interventions.

Keywords: Helicobacter; cancer; cholangiocarcinoma; neoplasms.

PubMed Disclaimer

Conflict of interest statement

M.R.-P. received lecture fees from Astellas, Chiesi, and Advanz pharma, none of them related to the present work. The remaining authors have no conflict of interest to disclose.

Figures

Figure 1
Figure 1
Flow diagram of the literature search and study selection.
Figure 2
Figure 2
Forest plot of 18 studies evaluating the risk of hepatobiliary tract malignancies according to the presence or absence of Helicobacter spp. infection detected by direct microbiological methods using a random-effects model.
Figure 3
Figure 3
Funnel plot of 18 studies, including evaluating the risk of hepatobiliary tract malignancies according to the presence or absence of Helicobacter spp. infection detected by direct microbiological methods using a random-effects model.
Figure 4
Figure 4
Forest plots of studies evaluating the risk of hepatobiliary tract malignancies according to the presence or absence of Helicobacter spp. infection assessed in different types of specimens: panel (A): bile; panel (B): gastric tissue; panel (C): liver/biliary tissue; panel (D): serum.
Figure 4
Figure 4
Forest plots of studies evaluating the risk of hepatobiliary tract malignancies according to the presence or absence of Helicobacter spp. infection assessed in different types of specimens: panel (A): bile; panel (B): gastric tissue; panel (C): liver/biliary tissue; panel (D): serum.

Similar articles

Cited by

References

    1. de Martel C., Franceschi S. Infections and Cancer: Established Associations and New Hypotheses. Crit. Rev. Oncol. Hematol. 2009;70:183–194. doi: 10.1016/j.critrevonc.2008.07.021. - DOI - PubMed
    1. Murata M. Inflammation and Cancer. Environ. Health Prev. Med. 2018;23:1–8. doi: 10.1186/s12199-018-0740-1. - DOI - PMC - PubMed
    1. de Martel C., Georges D., Bray F., Ferlay J., Clifford G.M. Global Burden of Cancer Attributable to Infections in 2018: A Worldwide Incidence Analysis. Lancet Glob. Heal. 2020;8:e180–e190. doi: 10.1016/S2214-109X(19)30488-7. - DOI - PubMed
    1. Sung H., Ferlay J., Siegel R.L., Laversanne M., Soerjomataram I., Jemal A., Bray F. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA. Cancer J. Clin. 2021;71:209–249. doi: 10.3322/caac.21660. - DOI - PubMed
    1. McGuigan A., Kelly P., Turkington R.C., Jones C., Coleman H.G., McCain R.S. Pancreatic Cancer: A Review of Clinical Diagnosis, Epidemiology, Treatment and Outcomes. World J. Gastroenterol. 2018;24:4846–4861. doi: 10.3748/wjg.v24.i43.4846. - DOI - PMC - PubMed

LinkOut - more resources